# colorectal cancer - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 3704
- Completion tokens: 18303
- Reasoning tokens: 
- Total tokens: 22007
- API requests reported: 
- Elapsed seconds: 196.909
- Final benchmark system: raw; file rank 2/5; original repeat 2; model vendor: DeepSeek

---
# Multidimensional Interpretation of Prognostic Transcriptomic Results in Colorectal Cancer

## 1. Overall biological interpretation

The provided colorectal cancer overall-survival results describe two opposing transcriptomic axes.

- **Poor prognosis (HR > 1)** is enriched for genes associated with a **mesenchymal / invasive / de-differentiated phenotype**: activin/TGFβ-superfamily signaling (`INHBB`), EMT-associated long non-coding RNA (`ZEB1-AS1`), cytoskeletal and migration regulators (`DCBLD2`, `TPM4`, `ABL2`, `MAP1B`, `NIN`, `NAV3`), matrix / adhesion remodeling (`ITGBL1`, `ADAMTS18`, `MSLN`, `SCEL`), oncogenic growth-factor signaling (`FGF19`, `AKT3`), glucose uptake (`SLC2A3`), and adenosine-mediated immunosuppression (`NT5E`).
- **Favorable prognosis (HR < 1)** is enriched for genes that mark **well-differentiated intestinal epithelium**: `CDX2`, `CDX1`, `LGALS4`, `MYO5B`, `PRR15L`, `RAB11FIP4`; and for **mitochondrial oxidative metabolism / amino-acid catabolism**: `NDUFA9`, `ATP5B`, `ATP5G1`, `COA3`, `TIMM13`, `CS`, `OGDHL`, `MCCC2`, `ACSS2`, `ASL`.

This pattern is biologically coherent: in colorectal cancer, loss of intestinal differentiation and acquisition of mesenchymal / EMT-like features are repeatedly associated with aggressive disease and poor survival. The protective mitochondrial / metabolic signal may reflect a more differentiated, metabolically stable tumor epithelium rather than a simple “OXPHOS-good” effect independent of differentiation.

The current evidence is **prognostic association**, not causal. However, the convergence of many independent genes onto a small number of biological axes strongly suggests that the data reflect clinically meaningful biology rather than isolated gene noise.

---

## 2. Core biological programs

### 2.1 TGFβ / activin-driven EMT and cytoskeletal-matrix remodeling  
**Direction:** Risk-associated (HR > 1)  
**Supporting genes:** `INHBB`, `ZEB1-AS1`, `DCBLD2`, `TPM4`, `ITGBL1`, `ABL2`, `MAP1B`, `NIN`, `NAV3`, `ADAMTS18`, `MSLN`, `SCEL`  
**Pathway:** Hallmark *Epithelial–Mesenchymal Transition*; Reactome *Signaling by TGF-beta family members*; KEGG *Focal adhesion* / *ECM-receptor interaction*  
**Interpretation:** `INHBB` encodes activin/inhibin βB, a TGFβ-superfamily ligand that can promote EMT and stromal crosstalk. `ZEB1-AS1` is an antisense transcript implicated in upregulating the EMT master transcription factor ZEB1. Cytoskeletal / motility genes (`TPM4`, `ABL2`, `MAP1B`, `NIN`, `NAV3`) and matrix / adhesion genes (`ITGBL1`, `ADAMTS18`, `MSLN`) collectively support an invasive, pro-metastatic phenotype. The consistency of direction across multiple genes is strong.  
**Strength and limitations:** Strong gene-level convergence; however, some of these genes may be expressed by cancer-associated fibroblasts or stromal cells rather than tumor cells, so tumor-cell-intrinsic EMT cannot be concluded from this table alone.

---

### 2.2 Intestinal epithelial differentiation and apical-basal homeostasis  
**Direction:** Protective (HR < 1)  
**Supporting genes:** `CDX2`, `CDX1`, `LGALS4`, `MYO5B`, `PRR15L`, `RAB11FIP4`  
**Pathway:** GO *epithelial cell differentiation*; Reactome *Digestion and absorption*  
**Interpretation:** `CDX2` and `CDX1` are ParaHox transcription factors that maintain intestinal identity. `LGALS4` encodes galectin-4, an enterocyte-associated protein; `MYO5B` and `RAB11FIP4` are involved in apical vesicle trafficking and brush-border maintenance. Their protective direction fits the established observation that low CDX2 expression is associated with poor prognosis and a less differentiated, more aggressive CRC subtype.  
**Strength and limitations:** Biologically compelling and supported by independent clinical CRC literature. The main limitation is that these genes may partly reflect normal epithelial content in the bulk tumor sample; differentiation status may also be a consequence of other driver alterations.

---

### 2.3 Mitochondrial oxidative metabolism and amino-acid / carbon catabolism  
**Direction:** Protective (HR < 1)  
**Supporting genes:** `NDUFA9`, `ATP5B`, `ATP5G1`, `ATP23`, `COA3`, `TIMM13`, `CS`, `OGDHL`, `MCCC2`, `ACSS2`, `ASL`, `ILVBL`, `GLYCTK`  
**Pathway:** Hallmark *Oxidative Phosphorylation*; KEGG *Citrate cycle (TCA cycle)*; Reactome *The citric acid (TCA) cycle and respiratory electron transport*  
**Interpretation:** Multiple independent components of mitochondrial energy metabolism are protective. `NDUFA9`, `ATP5B`, and `ATP5G1` are subunits of respiratory complexes; `COA3` and `TIMM13` contribute to mitochondrial complex assembly / import; `CS` and `OGDHL` are TCA-cycle enzymes; `MCCC2`, `ASL`, `ILVBL`, and `GLYCTK` participate in amino-acid / small-molecule catabolism. This suggests that a more oxidative, differentiated metabolic state is favorable relative to a glycolytic / biosynthetic aggressive state.  
**Strength and limitations:** Supported by many genes and clear pathway coherence. However, this signal may be tightly linked to the differentiation program, and could also be affected by tumor purity and stromal content.

---

### 2.4 Oncogenic signaling and nutrient-stress adaptation  
**Direction:** Risk-associated (HR > 1)  
**Supporting genes:** `AKT3`, `FGF19`, `SLC2A3`, `GADD45B`, `CYP1B1`, `LRRC8A`, `GJB6`  
**Pathway:** Hallmark *PI3K/AKT/mTOR Signaling*; KEGG *HIF-1 signaling pathway*; Hallmark *Glycolysis*  
**Interpretation:** `AKT3` is a direct PI3K/AKT pathway effector; `FGF19` is a growth-factor ligand able to signal through FGFRs; `SLC2A3` (GLUT3) supports glucose uptake under nutrient stress; `GADD45B` is a stress-response gene; `CYP1B1` is a xenobiotic-metabolizing enzyme with reported oncogenic roles. The direction of these associations is consistent with an aggressive, growth-factor-driven, metabolically adaptive tumor phenotype.  
**Strength and limitations:** Coherent but less gene-rich than the EMT or differentiation programs. There is also partial biological overlap with EMT, since PI3K/AKT signaling can promote EMT and invasion.

---

### 2.5 Tumor–immune interface: adenosine signaling vs antigen presentation  
**Direction:** Mixed — `NT5E` risk; `TAPBPL` and `LGALS9` protective  
**Supporting genes:** `NT5E`, `TAPBPL`, `LGALS9`  
**Pathway:** KEGG *Antigen processing and presentation*; Reactome *Immunoregulatory interactions between a lymphoid and a non-lymphoid cell*  
**Interpretation:** `NT5E` (CD73) generates extracellular adenosine, a potent immunosuppressive signal that can impair T-cell function. `TAPBPL` is involved in MHC class I antigen presentation and therefore immune surveillance. `LGALS9` is more complex: galectin-9 can regulate T-cell responses through TIM-3, but its net effect in CRC is context-dependent. The protective direction of `TAPBPL` / `LGALS9` suggests that immune recognition may be beneficial, while `NT5E` may contribute to immune evasion.  
**Strength and limitations:** Only a small number of genes support this program, and `LGALS9` biology is not unidirectional across cancer types. Without immune-cell composition data, this remains a plausible but less certain interpretation.

---

## 3. Key genes and interaction modules

### 3.1 CDX2 — protective, intestinal master regulator  
- **Current data:** HR ≈ 0.75, FDR < 0.05.  
- **Potential role:** Master transcription factor for intestinal differentiation; loss of CDX2 is associated with aggressive CRC.  
- **Gene-gene relationship:** Regulatory relationship with intestinal target genes such as `LGALS4` and `MYO5B`; no direct physical interaction is implied from this dataset.  
- **Evidence:** Direct prognostic association in input; independent CRC literature and clinical outcome data.

### 3.2 CDX1 / LGALS4 / MYO5B — protective, differentiated enterocyte module  
- **Current data:** All protective: `CDX1` HR ≈ 0.78, `LGALS4` HR ≈ 0.77, `MYO5B` HR ≈ 0.75.  
- **Potential role:** Maintenance of enterocyte differentiation, microvillus / apical trafficking, and epithelial homeostasis.  
- **Gene-gene relationship:** Likely co-regulated by CDX2 and co-expressed in differentiated epithelium; `MYO5B` and `RAB11FIP4` are pathway co-members in apical recycling / trafficking. No direct physical interaction should be assumed without experimental evidence.  
- **Evidence:** Direct survival associations; tissue-specific expression evidence in intestinal epithelium.

### 3.3 INHBB — risk, TGFβ/activin ligand  
- **Current data:** HR ≈ 1.43, one of the strongest risk signals.  
- **Potential role:** Activin/inhibin βB subunit; can activate TGFβ-superfamily signaling, EMT, and stromal remodeling.  
- **Gene-gene relationship:** Direct ligand-receptor relationship with activin receptors, but this is inferred from literature and pathway knowledge rather than from the current dataset.  
- **Evidence:** Direct survival association; pathway / ontology evidence; literature evidence in cancer EMT.

### 3.4 ZEB1-AS1 — risk, EMT-associated lncRNA  
- **Current data:** HR ≈ 1.37.  
- **Potential role:** Antisense lncRNA reported to stabilize or upregulate ZEB1, an EMT transcription factor.  
- **Gene-gene relationship:** Regulatory interaction with `ZEB1`; this is not a direct physical protein-protein interaction. `ZEB1` itself is not present in the input list, so the link is inferred from literature.  
- **Evidence:** Direct survival association; external regulatory evidence; pathway co-membership with EMT.

### 3.5 NT5E / CD73 — risk, immunosuppression and metastasis  
- **Current data:** HR ≈ 1.31.  
- **Potential role:** Cell-surface ectonucleotidase that converts AMP to adenosine, contributing to immune suppression and tumor progression.  
- **Gene-gene relationship:** Indirect/putative relationship with immune cells via extracellular adenosine and adenosine receptors; no direct physical interaction with the other listed genes is supported by this dataset.  
- **Evidence:** Direct survival association; strong literature evidence in other cancers; drug-development interest, though drug existence alone does not prove efficacy in CRC.

### 3.6 TAPBPL — protective, antigen processing  
- **Current data:** HR ≈ 0.71.  
- **Potential role:** MHC class I antigen-processing pathway; could promote tumor immunogenicity and immune surveillance.  
- **Gene-gene relationship:** Pathway co-membership with TAP1/TAP2/tapasin in antigen processing; not a direct interaction demonstrated here.  
- **Evidence:** Direct survival association; pathway / ontology evidence.

### 3.7 Mitochondrial OXPHOS module — protective  
- **Supporting genes:** `NDUFA9`, `ATP5B`, `ATP5G1`, `COA3`, `TIMM13`.  
- **Current data:** All protective.  
- **Potential role:** Sustaining mitochondrial ATP production, oxidative metabolism, and mitochondrial protein homeostasis.  
- **Gene-gene relationship:** `NDUFA9` is a physical subunit of Complex I; `ATP5B` and `ATP5G1` are physical subunits of Complex V; `COA3` and `TIMM13` participate in mitochondrial assembly/import. Across complexes, they are pathway co-members rather than direct interaction partners.  
- **Evidence:** Multiple independent genes with coherent protective direction; curated biochemical pathway evidence.

### 3.8 FGF19 / AKT3 / SLC2A3 — risk, growth-factor signaling and glucose metabolism  
- **Current data:** `FGF19` HR ≈ 1.29, `AKT3` HR ≈ 1.32, `SLC2A3` HR ≈ 1.28.  
- **Potential role:** Oncogenic growth-factor signaling, PI3K/AKT activation, and glucose uptake.  
- **Gene-gene relationship:** Likely pathway co-membership: FGF19→FGFR→PI3K/AKT→increased glucose transporter expression. Some relationships are direct (FGF19 with its receptor), others are downstream / indirect.  
- **Evidence:** Direct survival associations; pathway annotation; literature in other cancer types. This is a supported hypothesis rather than established CRC-specific biology.

### 3.9 MYB — protective but uncertain  
- **Current data:** HR ≈ 0.77.  
- **Potential role:** Transcription factor with context-dependent oncogenic and differentiation-related functions. In intestinal epithelium, MYB has roles in proliferation and differentiation; however, in many other contexts it is considered an oncogene.  
- **Gene-gene relationship:** Unknown from the current dataset; possible co-expression with differentiated intestinal genes, but no direct or regulatory relationship should be inferred.  
- **Evidence:** Direct survival association only. The protective direction conflicts with some literature reporting oncogenic MYB activity, so this should be treated as exploratory and requiring validation.

---

## 4. Validation priorities

### 4.1 Biomarker signature validation  
**Type:** Biomarker  
**Priority:** Build and test a compact prognostic signature using both protective differentiation/metabolism genes and risk EMT/immune genes, such as `CDX2`, `LGALS4`, `MYO5B`, `NDUFA9`, `INHBB`, `ZEB1-AS1`, and `NT5E`.  
**Why:** The current data suggest that prognosis is linked to a balance between differentiation and EMT/immune evasion. A multi-gene signature would be more robust than any single gene.  
**Current evidence:** Direct HR associations in the provided table.  
**External evidence:** Independent CRC cohorts have well-established prognostic roles for CDX2 and CD73.  
**Next step:** Validate in independent CRC cohorts (e.g., TCGA-COAD/READ, GSE39582) using multivariable Cox models adjusted for stage, MSI, age, and treatment.  
**Conclusion status:** Exploratory hypothesis.

---

### 4.2 Tumor-composition and confounding check  
**Type:** Confounding or composition check  
**Priority:** High, because many risk genes (`INHBB`, `ITGBL1`, `MSLN`, `NT5E`) could be expressed by cancer-associated fibroblasts, endothelial cells, or immune cells, while protective genes (`CDX2`, `LGALS4`, `MYO5B`) are strongly epithelial.  
**Why:** Without this check, the observed survival associations might reflect the proportion of tumor, stroma, or normal epithelium rather than a tumor-cell-intrinsic program.  
**Current evidence:** The input is bulk-tissue expression; no cell-composition or tumor-purity data are provided.  
**External evidence:** CRC is known to contain abundant stroma; CMS4 tumors are stroma-rich and have poor prognosis.  
**Next step:** Perform cell-type deconvolution (CIBERSORTx, xCell, or similar), single-cell RNA-seq, or spatially resolved transcriptomics; validate key proteins by immunohistochemistry.  
**Conclusion status:** Necessary check; current causal or cell-intrinsic conclusions are not established.

---

### 4.3 Mechanistic validation of CDX2 and EMT axis  
**Type:** Mechanistic hypothesis  
**Priority:** Test whether loss of CDX2 and activation of ZEB1-AS1 / INHBB directly drive the poor-prognosis phenotype.  
**Why:** CDX2 and ZEB1-AS1 sit at the center of two opposing biological programs.  
**Current evidence:** Prognostic associations only.  
**External evidence:** CDX2 loss promotes invasion and poor differentiation in CRC models; ZEB1-AS1 is reported to regulate ZEB1 and EMT.  
**Next step:** Use CRC organoids / cell lines with CDX2 knockdown or overexpression, ZEB1-AS1 perturbation, and activin/TGFβ stimulation; assess migration, invasion, EMT markers, and intestinal differentiation markers.  
**Conclusion status:** Supported hypothesis for CDX2; exploratory for ZEB1-AS1 and INHBB.

---

### 4.4 Therapeutic-target evaluation of CD73 / NT5E  
**Type:** Therapeutic target  
**Priority:** Moderate-high, because CD73 is an established immunotherapeutic target in other cancers and its high expression is associated with poor prognosis here.  
**Why:** The risk association of `NT5E` suggests that adenosine-mediated immune suppression may contribute to poor survival.  
**Current evidence:** HR ≈ 1.31.  
**External evidence:** CD73 inhibitors are in clinical development; CD73 expression is associated with poor outcome in several cancer types. However, drug existence does not by itself establish efficacy in colorectal cancer.  
**Next step:** Test CD73 inhibition in immune-competent CRC models with high NT5E expression; measure tumor growth, metastasis, T-cell infiltration, and adenosine levels.  
**Conclusion status:** Exploratory hypothesis.

---

### 4.5 Interaction / network validation  
**Type:** Interaction / network hypothesis  
**Priority:** Confirm or refute the proposed regulatory relationships among ZEB1-AS1/ZEB1, CDX2/intestinal targets, and mitochondrial/differentiation coupling.  
**Why:** These links are biologically plausible but are not demonstrated by the current dataset.  
**Current evidence:** Co-occurrence of gene-level prognostic associations; no direct interaction data.  
**External evidence:** Literature provides some support for ZEB1-AS1/ZEB1 regulation and CDX2 regulation of intestinal genes; the link between CDX2 and mitochondrial gene expression is less established.  
**Next step:** RNA-seq / ChIP-seq / Ribo-seq after perturbation; antisense RNA pulldown for ZEB1-AS1; chromatin immunoprecipitation for CDX2 at target promoters.  
**Conclusion status:** Exploratory hypothesis.

---

## 5. Evidence grounding

- **Direct dataset evidence:** All statistical conclusions come only from the provided HR, P, and FDR values. This is the only quantitative evidence used for prognostic associations.
- **Pathway/ontology evidence:** Curated pathway annotations support grouping genes into EMT, OXPHOS, intestinal differentiation, PI3K/AKT, and antigen processing. This evidence is **not independent** of gene identity, because the same gene annotations depend on the same biological knowledge.
- **Protein interaction / regulatory evidence:** Some gene-gene relationships are supported by published physical or regulatory interactions (e.g., ZEB1-AS1/ZEB1, INHBB/activin receptors, NDUFA9/Complex I). These are external evidence and should not be interpreted as coming from the input dataset.
- **Disease-association evidence:** Independent CRC literature supports CDX2 low expression and CD73/NT5E as poor-prognosis markers. This is independent of the input table and strengthens the interpretation for those genes, but it does not prove causation.
- **Expression/tissue-specific evidence:** CDX2, CDX1, LGALS4, and MYO5B are known intestinal-epithelial markers. This supports the interpretation that the protective signal reflects differentiated epithelial identity.
- **Genetic/clinical evidence:** No germline or somatic genetic data are provided, and no clinical adjustment is available. Thus, clinical specificity is limited.
- **Drug/therapeutic evidence:** NT5E/CD73 inhibitors exist, but this is not evidence that NT5E is an effective CRC target in the absence of functional validation.
- **Conflicts:** `MYB` is the clearest conflict: it is protective in this table but has oncogenic roles in other contexts. `LGALS9` also has context-dependent immune functions. These should be interpreted cautiously.

---

## 6. Limitations and alternative explanations

### 6.1 Tumor purity and cell-composition differences  
Bulk colorectal tumors contain variable amounts of stroma, immune cells, and normal epithelium. Genes such as `INHBB`, `ITGBL1`, `NT5E`, and `MSLN` may be highly expressed by non-malignant cells. Protective differentiation genes may simply indicate a higher fraction of well-differentiated tumor epithelium or normal mucosal contamination.  
**How to address:** Deconvolution, single-cell RNA-seq, spatial transcriptomics, and IHC.

### 6.2 Confounding by stage, grade, treatment, or molecular subtype  
If high-stage tumors have more EMT and less differentiation, the observed HRs may partly reflect disease severity rather than independent gene function. Treatment exposure and MSI status are also unknown and could influence survival.  
**How to address:** Multivariable Cox regression with stage, age, sex, MSI, and treatment; validation in independent cohorts with clinical annotations.

### 6.3 Multiple testing and borderline FDR  
Several genes have FDR values above 0.05 (e.g., `LGALS4`, `CDX1`, `FGF19`, `CRYM`), so some results may represent false positives or marginal associations. The table also includes unannotated probes and multi-gene assignments.  
**How to address:** Pre-specify FDR thresholds; replicate in independent datasets; exclude ambiguous probes from core conclusions.

### 6.4 Association vs causation  
This is a prognostic analysis, not a perturbation study. A gene can be associated with survival because it reflects the tumor subtype, because it is co-expressed with a driver, or because it is expressed by a particular cell population. Survival association alone cannot establish a biological mechanism.  
**How to address:** Functional experiments in model systems; genetic perturbation; in vivo metastasis assays.

### 6.5 Broad or overlapping pathways  
Programs such as EMT, PI3K/AKT signaling, and metabolic reprogramming are not fully independent. Many risk genes may belong to several overlapping networks. Therefore, the current interpretation should be considered an integrated hypothesis, not a set of fully separable biological programs.  
**How to address:** Use network-based methods and formal pathway enrichment with permutation testing on independent data.

---

## Summary statement

The provided prognostic transcriptomic data support a coherent model in which **poor prognosis in colorectal cancer is associated with loss of intestinal differentiation, acquisition of EMT/mesenchymal features, oncogenic growth-factor signaling, and immune suppression**, while **favorable prognosis is associated with preservation of intestinal epithelial identity and mitochondrial oxidative metabolism**. These conclusions are well supported as prognostic associations and as a biological hypothesis, but they should not be treated as established causal mechanisms until validated in independent cohorts and experimental systems.
